18F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Neuroinflammation is considered an important pathway associated with several diseases that result in cognitive decline. 18F-THK5351 positron emission tomography (PET) signals might indicate the presence of neuroinflammation, as well as Alzheimer’sdisease-type tau aggregates. β-amyloid (Aβ)-negative (Aβ–) amnestic mild cognitive impairment (aMCI) may be associatedwith non-Alzheimer’s disease pathophysiology. Accordingly, we investigated associations between 18F-THK5351 PETpositivity and cognitive decline among Aβ– aMCI patients. Materials and Methods: The present study included 25 amyloid PET negative aMCI patients who underwent a minimum of twofollow-up neuropsychological evaluations, including clinical dementia rating-sum of boxes (CDR-SOB). The patients were classifiedinto two groups: 18F-THK5351-positive and -negative groups. The present study used a linear mixed effects model to estimatethe effects of 18F-THK5351 PET positivity on cognitive prognosis among Aβ– aMCI patients. Results: Among the 25 Aβ– aMCI patients, 10 (40.0%) were 18F-THK5351 positive. The patients in the 18F-THK5351-positive groupwere older than those in the 18F-THK5351-negative group (77.4±2.2 years vs. 70.0±5.5 years; p<0.001). There was no difference betweenthe two groups with regard to the proportion of apolipoprotein E ε4 carriers. Interestingly, however, the CDR-SOB scores ofthe 18F-THK5351-positive group deteriorated at a faster rate than those of the 18F-THK5351-negative group (B=0.003, p=0.033). Conclusion: The results of the present study suggest that increased 18F-THK5351 uptake might be a useful predictor of poor prognosisamong Aβ– aMCI patients, which might be associated with increased neuroinflammation (ClinicalTrials.gov NCT02656498).
Abstract
Purpose: Neuroinflammation is considered an important pathway associated with several diseases that result in cognitive decline. 18F-THK5351 positron emission tomography (PET) signals might indicate the presence of neuroinflammation, as well as Alzheimer’sdisease-type tau aggregates. β-amyloid (Aβ)-negative (Aβ–) amnestic mild cognitive impairment (aMCI) may be associatedwith non-Alzheimer’s disease pathophysiology. Accordingly, we investigated associations between 18F-THK5351 PETpositivity and cognitive decline among Aβ– aMCI patients. Materials and Methods: The present study included 25 amyloid PET negative aMCI patients who underwent a minimum of twofollow-up neuropsychological evaluations, including clinical dementia rating-sum of boxes (CDR-SOB). The patients were classifiedinto two groups: 18F-THK5351-positive and -negative groups. The present study used a linear mixed effects model to estimatethe effects of 18F-THK5351 PET positivity on cognitive prognosis among Aβ– aMCI patients. Results: Among the 25 Aβ– aMCI patients, 10 (40.0%) were 18F-THK5351 positive. The patients in the 18F-THK5351-positive groupwere older than those in the 18F-THK5351-negative group (77.4±2.2 years vs. 70.0±5.5 years; p<0.001). There was no difference betweenthe two groups with regard to the proportion of apolipoprotein E ε4 carriers. Interestingly, however, the CDR-SOB scores ofthe 18F-THK5351-positive group deteriorated at a faster rate than those of the 18F-THK5351-negative group (B=0.003, p=0.033). Conclusion: The results of the present study suggest that increased 18F-THK5351 uptake might be a useful predictor of poor prognosisamong Aβ– aMCI patients, which might be associated with increased neuroinflammation (ClinicalTrials.gov NCT02656498).
참고문헌 (32)
- Alonso AC, "Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules", Nat Med, 2, pp.783~787 (1996)
- Harada R, "18F-THK5351 : a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease", J Nucl Med, 57, pp.208~214 (2016)
- THK-5351, "PLoS One", 2016, e0158460~
- Lee MK, "1-methyl-2-undecyl-4(1H)-quinolone as an irreversible and selective inhibitor of type B monoamine oxidase", Chem Pharm Bull(Tokyo), 51, pp.409~411 (2003)
- Ng KP, "Monoamine oxidase B inhibitor, selegiline, reduces 18FTHK5351uptake in the human brain", Alzheimers Res Ther, 9, pp.25~ (2017)
- Harada R, "Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease", J Nucl Med, 59, pp.671~674 (2018)
- THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia, "Eur J Nucl Med Mol Imaging", 2018, 432~442
- Jang H, "Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers", Neuroimage Clin, 24, pp.101941~ (2019)
- Kim SE, "A nomogram for predicting amyloid PET positivity in amnestic mild cognitive impairment", J Alzheimers Dis, 66, pp.681~691 (2018)
- Ezzati A, "Predicting amyloid-β levels in amnestic mild cognitive impairment using machine learning techniques", J Alzheimers Dis, 73, pp.1211~1219 (2020)
- Ye BS, "Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments : a three-year longitudinal study", Sci Rep, 8, pp.5557~ (2018)
- Ye BS, "Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments : comparison with amyloid-positive mild cognitive impairment", Neurobiol Aging, 35, pp.291~300 (2014)
- Stefaniak J, "Imaging of neuroinflammation in dementia : a review", J Neurol Neurosurg Psychiatry, 87, pp.21~28 (2016)
- Pasqualetti G, "The role of neuroinflammation in dementias", Curr Neurol Neurosci Rep, 15, pp.17~ (2015)
- Petersen RC, "Mild cognitive impairment : clinical characterization and outcome", Arch Neurol, 56, pp.303~308 (1999)
- Son HJ, "Differences in gray and white matter 18F-THK5351 uptake between behavioralvariant frontotemporal dementia and other dementias", Eur J Nucl Med Mol Imaging, 46, pp.357~366 (2019)
- Park JE, "Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer’s disease differ according to disease severity and amyloid positivity", PLoS One, 14, pp.e0226265~ (2019)
- Cho SH, "Head-tohead comparison of 18F-florbetaben and 18F-flutemetamol in the cortical and striatal regions", J Alzheimers Dis, 76, pp.281~290 (2020)
- Tzourio-Mazoyer N, "Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain", Neuroimage, 15, pp.273~289 (2002)
- Klunk WE, "The centiloid project : standardizing quantitative amyloid plaque estimation by PET", Alzheimers Dement, 11, pp.1-15.e1~1-15.e4 (2015)
- Barthel H, "Cerebral amyloid-β PET with florbetaben(18F)in patients with Alzheimer’s disease and healthy controls : a multicentre phase 2diagnostic study", Lancet Neurol, 10, pp.424~435 (2011)
- Kang Y, "Seoul neuropsychological screening battery" (2003), Human Brain Research & Consulting Co
- 강성훈, "The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum", Dementia and Neurocognitive Disorders(대한치매학회지), 18(3), pp.77~95 (2019), 대한치매학회[DOI]
- Ossenkoppele R, "The impact of demographic, clinical, genetic, and imaging variables on tau PET status", Eur J Nucl Med Mol Imaging, 48, pp.2245~2258 (2021)
- Smith R, "The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects", Brain, 143, pp.3805~3815 (2020)
- Kim HJ, "THK5351and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient : a case report", BMC Neurol, 19, pp.211~ (2019)
- THK5351 PET in progressive supranuclear palsy, "Acta Neuropathol Commun", 2018, 53~
- Ezura M, "Longitudinal changes in 18F-THK5351 positron emission tomography in corticobasal syndrome", Eur J Neurol, 26, pp.1205~1211 (2019)
- Morris JC, "Clinical dementia rating : a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type", Int Psychogeriatr, 9, pp.173~176 (1997)
- RansohoffRM, "How neuroinflammation contributes to neurodegeneration", Science, 353, pp.777~783 (2016)
- Abu-Rumeileh S, "CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia", Alzheimers Res Ther, 12, pp.2~ (2020)
- Cho SH, "Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments", Sci Rep, 10, pp.19576~ (2020)